Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAT2A | P31153 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11002375 | 0.89 | ALDH1A1 (0.56) | MAPTTSHRALDH1A1GAAHPGD | |
| SCHEMBL10999963 | 0.87 | CA12 (0.47) | MAPTTSHRALDH1A1GAAHPGD | |
| SCHEMBL29691263 | 0.86 | NPSR1 (0.56) | MAPTTSHRALDH1A1HPGDNPSR1 | |
| SCHEMBL10964546 | 0.86 | LMNA (0.49) | MAPTTSHRALDH1A1GAAHPGD | |
| SCHEMBL11004340 | 0.85 | ALDH1A1 (0.49) | MAPTALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL10924474 | 0.84 | HTT (0.44) | MAPTTSHRALDH1A1GAAHPGD | |
| SCHEMBL10998352 | 0.82 | MAPT (0.54) | MAPTALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL10923940 | 0.81 | PDE4B (0.53) | MAPTTSHRALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL11000015 | 0.78 | KDM4E (0.45) | MAPTTSHRALDH1A1HPGDNPSR1 | |
| SCHEMBL20187298 | 0.78 | TSHR (0.53) | MAPTTSHRALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2044055-A2 | AMIDE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-4537886-A | β-lactam antibacterial agents and compositions containing them | BEECHAM GROUP P.L.C. (GB) | 1985-08-27 | — | — | US | disclosed |
| EP-0090656-A1 | Penicillins, a process for the preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | MAPT 1448/4885TSHR 2511/4885ALDH1A1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.